Transcatheter Heart Valve Patents: Top Companies & Trends 2026
A data-backed look at transcatheter heart valve patents: who leads filings, how the technology composition breaks down by IPC subclass, and where filing activity is heading through 2026.
Filing growth = 2021 (108 records) → 2024 (56); 2024 is the last year we treat as complete. Top-5 share = the 5 largest assignees ÷ all 1,204 records in scope (CR5), not the ranked leaders only.
What the transcatheter heart valve patent record shows
Transcatheter heart valve devices sit at the intersection of implant design, delivery mechanics and imaging-guided placement. The 1,204 records in scope, filed between 2015 and the 2026 data cut-off, cluster overwhelmingly around implant and prosthesis claims rather than the surrounding delivery or sterilisation art. Publication lags filing by roughly 18 months, so the most recent filing years in this dataset understate real activity — treat 2024 as the last year with a settled count.
The record splits cleanly into a small set of high-volume filers and a long tail of single or occasional filers, a pattern that shapes both licensing leverage and where a new entrant's claims are likely to collide with prior art. Receiving-office data shows the United States as the dominant filing venue, with Europe and the PCT route well behind it and China, Canada and Australia trailing further still.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trends and technology composition
Two views of the same 1,204 records: how filing volume has moved year over year, and how those records distribute across IPC subclasses.
Filing activity rose to a 2021 peak, then pulled back
Annual filings ran from 61 in 2017 to a peak of 108 in 2021, then dropped to 56 by 2024 — a 48% decline over that three-year span. 2025 and 2026 figures are still filling in given publication lag, so read the tail of the trend as incomplete rather than as evidence of a slowdown.
Publication lags filing by roughly 18 months, so 2025 onwards are still filling in. Growth rates on this page therefore end at 2024; running them to the last bar would understate the field.
Implant and prosthesis claims dominate the classification mix
A61F (implants and prostheses) appears on 88.7% of the 1,204 records, far ahead of A61B (diagnosis and surgery, 11.1%) and A61M (devices for body fluids, 8.8%). Sterilising, spraying, plumbing fittings, additive manufacturing and educational-aid classes each sit under 2% of records, marking them as thin adjacent branches rather than core claim territory.
Shares are the percentage of the 1,204 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Cardiovascular Devices: Transcatheter Heart Valve Patent Landscape with Eureka
This page is one run against one query. Ask Eureka your own question about cardiovascular devices: transcatheter heart valve patent landscape and every answer comes back with the patent numbers behind it.
Try EurekaThe records anchoring this landscape
Transcatheter heart valve prosthesis systems and methods for rotational alignment (US20220175524A1)
Methods for rotationally aligning a transcatheter heart valve prosthesis within a native heart valve during percutaneous delivery, using at least one imaging marker and cusp-overlap or coronary-overlap viewing angle images to determine and adjust rotational orientation before final deployment.Filed by Medtronic, Inc. — dated 2022-06-09.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US7993394B2 | Low profile transcatheter heart valve | 1,396 |
| 2 | US20090281619A1 | Low Profile Delivery System for Transcatheter Heart Valve | 1,213 |
| 3 | US20040210307A1 | Percutaneous transcatheter heart valve replacement | 1,039 |
| 4 | US7175656B2 | Percutaneous transcatheter heart valve replacement | 686 |
| 5 | US20100036484A1 | Low profile transcatheter heart valve | 620 |
| 6 | US20150142103A1 | Multi-component designs for heart valve retrieval device, sealing structures and stent assembly | 560 |
| 7 | US8795357B2 | Perivalvular sealing for transcatheter heart valve | 491 |
| 8 | US8454685B2 | Low profile transcatheter heart valve | 464 |
| 9 | US20140343671A1 | Perivalvular sealing for transcatheter heart valve | 414 |
| 10 | WO2009149462A2 | Low profile transcatheter heart valve | 388 |
Citation counts reflect influence within the searched corpus and favour older filings; treat them as a signal of prior-art weight rather than current commercial relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers mean for a filing decision
Four read-outs from the dataset that matter more for strategy than for description.
The field is not fragmented
Five assignees hold 854 of the 1,204 records in scope, with the leader alone at 484. Any new filing in core implant claims is filing into ground already densely covered by a small number of players.
Peak activity has passed for now
Annual filings fell from a 2021 peak of 108 to 56 by 2024, the last year with a complete publication picture. That is a real pullback in the core claim space, not a data artefact — though 2025-26 counts are still incomplete.
Implant claims dominate, delivery and sterilisation trail
A61F (implants and prostheses) sits on the vast majority of records; A61B and A61M each cover roughly a tenth. Sterilising, spraying, plumbing and additive-manufacturing classes each sit under 2%, marking thin adjacent territory.
The US is the dominant office, Europe and PCT follow
United States filings lead at 453 records, ahead of the EPO at 244 and WIPO/PCT at 116. China, Canada and Australia each sit well below that, indicating where enforcement and freedom-to-operate checks matter most.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to cardiovascular devices: transcatheter heart valve patent landscape, with the prior art for and against each one.
| Assignee | Co-assignee | Shared families |
|---|---|---|
| Edwards Lifesciences | PELLED ITAI | 6 |
| St. Jude Medical Cardiology Division, Inc. | WANG HUISUN | 6 |
| Edwards Lifesciences | FELSEN BELLA | 5 |
| St. Jude Medical Cardiology Division, Inc. | St. Jude Medical, Inc. | 4 |
| St. Jude Medical Cardiology Division, Inc. | DALY JACOB J | 4 |
| Edwards Lifesciences | NITZAN YAACOV | 3 |
| Edwards Lifesciences | NGUYEN THIEN NH DIANA | 3 |
| Edwards Lifesciences | NGUYEN SON | 3 |
Only 10 co-assignee pairs appear across the dataset, and the strongest pairs cluster around the same two leading organisations — a sign that most invention here is filed solo rather than through joint development.
Where to take this analysis
The dataset points to a crowded implant core and a thinner set of adjacent branches. The next steps depend on whether you are filing, licensing or watching the field.
Map claims against the leading five before drafting
With 70.9% of records held by five assignees, a freedom-to-operate read against their portfolios should come before any new implant-claim drafting.
Run a claim comparison in EurekaWatch the thin adjacent classes
Additive manufacturing and educational/demonstration-aid classes sit under 1% of records each — worth checking for open claim space rather than assuming they are unclaimed.
Explore white space in EurekaTrack the 2025-26 filing tail as it settles
Publication lag means recent years are undercounted; revisit the trend once 2025 filings finish publishing to confirm whether the post-2021 pullback continues.
Set up a filing alert in EurekaCommon questions on transcatheter heart valve patents
The assignee ranking in this dataset shows a clear leader holding 484 of the 1,204 records in scope, with the top five combined accounting for 70.9% of all records. That concentration means a small number of organisations control most of the core implant claim space. Any new entrant should expect to file around, license from, or challenge one of these leading portfolios rather than find open ground in the core claims.
Filings rose from 61 in 2017 to a peak of 108 in 2021, then declined to 56 by 2024 — a 48% drop over that three-year span, and 2024 is the last year with a reasonably complete publication picture. That is a genuine pullback in filing volume rather than the field disappearing; it likely reflects the core implant claim space filling in. Figures for 2025 and 2026 are still incomplete because publication lags filing by roughly 18 months, so it is too early to call a continued decline.
The overwhelming majority — 88.7% of the 1,204 records — carry an A61F implant/prosthesis classification, making device and valve structure the dominant claim territory. Diagnosis and surgery (A61B, 11.1%) and body-fluid devices (A61M, 8.8%) are secondary but meaningful areas. Smaller adjacent classes such as additive manufacturing, sterilising equipment and educational aids each sit under 2% of records, indicating those branches are far less contested.
The classification data points toward the thin adjacent branches — additive manufacturing (B33Y, 0.9% of records) and educational/demonstration aids (G09B, 0.7%) — as areas with far less claim density than the core A61F implant space. That does not guarantee an open path, since low volume can also mean low commercial interest, but it is a more promising starting point for novel claims than the crowded implant core. A freedom-to-operate search focused specifically on those subclasses is a reasonable next step.
The United States leads by a wide margin at 453 filed records, followed by the European Patent Office at 244 and the WIPO/PCT route at 116. China, Canada and Australia follow well behind, at 74, 60 and 34 records respectively. For companies assessing enforcement risk or planning international filing strategy, the US and Europe are where the bulk of the competitive activity — and the litigation exposure — currently sits.
Research Cardiovascular Devices: Transcatheter Heart Valve Patent Landscape in depth with Eureka
Go past this page: query the whole cardiovascular devices: transcatheter heart valve patent landscape corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.